Showing results (541-550 of 1,988) with videos related to

Sort By:
Pageof 199
Prostate Cancer and Prostatic Diseases|October 8, 2021
Impact of diverticular disease on prostate cancer risk among hypertensive menNir Tomer, Dimple Chakravarty, Parita Ratnani, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Prostate Cancer and Prostatic Diseases|April 13, 2022
Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysisReza Sari Motlagh, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Prostate Cancer and Prostatic Diseases|January 29, 2022
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancerLui Shiong Lee, Adelene Y L Sim, Chee Wee Ong, et al.
Prostate Cancer and Prostatic Diseases|February 13, 2022
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard scoreMinh-Phuong Huynh-Le, Roshan Karunamuni, Chun Chieh Fan, et al.
Prostate Cancer and Prostatic Diseases|October 10, 2021
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patientsMichalis Liontos, Evangelos Terpos, Elena Kunadis, et al.
Prostate Cancer and Prostatic Diseases|April 17, 2022
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trialCarsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Prostate Cancer and Prostatic Diseases|April 15, 2022
The differential diagnostic value of dual-phase 18F-DCFPyL PET/CT in prostate carcinomaAijuan Tian, Runlong Lin, Jing Yu, et al.
Prostate Cancer and Prostatic Diseases|April 15, 2022
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approachesAna Paula Alarcón-Zendejas, Anna Scavuzzo, Miguel A Jiménez-Ríos, et al.
Prostate Cancer and Prostatic Diseases|December 6, 2023
Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databasesIrene M Shui, Mehmet Burcu, Changxia Shao, et al.
Pageof 199